A comparative review of available ADHD treatments, funded by the National Institute for Health and Care Research (NIHR) via a Research for Patient Benefit grant to Professor Samuele Cortese, NIHR Research Professor at the University of Southampton and senior co-author on the paper, provides the most comprehensive analysis to date of the effectiveness of pharmacological, psychological and neurostimulatory treatments for ADHD.
The paper, also supported by NIHR Applied Research Collaboration Oxford and Thames Valley, published in The Lancet Psychiatry, highlights that stimulants and atomoxetine are the only treatments with proven efficacy in reducing symptoms of ADHD in adults, as reported by both clinicians and patients.
The landmark study sets a new benchmark for evidence-based treatment recommendations for healthcare providers and policymakers and paves the way for future advancements in ADHD care.
This review collated and analysed data from 113 randomised controlled trials involving over 14,800 participants from different countries with a diagnosis of ADHD. The study assessed the efficacy of treatments in reducing core ADHD symptoms, alongside their acceptability and safety.
Stimulants, a group of medicines that stimulate parts of the brain to improve concentration and attention, and reduce impulsive and hyperactive behaviour, include methylphenidate, lisdexamfetamine, and dexamfetamine.
The drug atomoxetine works differently to stimulants as a selective noradrenaline reuptake inhibitor (SNRI), which increases the amount of a chemical in the brain called noradrenaline which can aid concentration and help control impulses.
Read the full story on the Department of Psychiatry website.
more recommended stories
-
Low Magnesium Intake and Cardiovascular Disease Risk
In a recent analysis published in.
-
Mei Nortley awarded inaugural Averil Mansfield Trainer of the Year Award — University of Oxford, Medical Sciences Division
The Rouleaux Club (Vascular Trainees’ Association.
-
The genetic basis of fertility, family and longevity — University of Oxford, Medical Sciences Division
Led by researchers from the University.
-
Radical rethink of mental health support for adolescents needed – new study — University of Oxford, Medical Sciences Division
The study, led by teams at.
-
New study reveals the COVID-19 pandemic’s impact on other causes of death — University of Oxford, Medical Sciences Division
Researchers from the Leverhulme Centre for Demographic.
-
A way to test the ability of red blood cells to deliver oxygen by measuring their shape — University of Oxford, Medical Sciences Division
FlowScore (1) – a formula developed.
-
Umbrella review of traumatic brain injury research — University of Oxford, Medical Sciences Division
Traumatic brain injury (TBI) is a.
-
New study reveals link between head injuries and viruses in Alzheimer’s Disease — University of Oxford, Medical Sciences Division
A new study suggests that repeated.
-
First patients scanned in new study investigating traumatic brain injury in young athletes — University of Oxford, Medical Sciences Division
Traumatic brain injury (TBI) is.
-
Wellcome Discovery Award of £5m to fund pioneering research to combat deadly diarrhoea — University of Oxford, Medical Sciences Division
Diarrhoeal disease is responsible for killing.
Leave a Comment